# Collaborative Prescribing Agreement

biosimilar rituximab, dimethyl fumarate, glatiramer acetate, interferon beta-1a, interferon beta-1b, and teriflunomide for the treatment of relapsing-remitting multiple sclerosis

This COLLABORATIVE PRESCRIBING AGREEMENT (the CPA or "Agreement") is entered into by the Pharmaceutical, Laboratory & Blood Services Division, Ministry of Health, B.C., and the undersigned neurologist.

To obtain a neurologist exemption from completing Special Authority requests for biosimilar rituximab, dimethyl fumarate, glatiramer acetate, interferon beta-1a (Avonex®, Rebif®), interferon beta-1b (Betaseron®, Extavia®), and teriflunomide for relapsing-remitting multiple sclerosis (MS), I,_____, a neurologist specializing in MS who practices at the MS clinic location indicated below, agree to prescribe according to the following Limited Coverage criteria.

☐ Fraser Health Multiple Sclerosis Clinic in Burnaby

☐ Kelowna General Hospital

☐ Multiple Sclerosis Clinic at UBC Hospital in Vancouver

☐ Multiple Sclerosis Clinic in Prince George

☐ Vancouver Island MS Clinic at Royal Jubilee Hospital in Victoria

☐ Vancouver Island MS Clinic at Nanaimo Regional Hospital in Nanaimo

| Special Authority Criteria | Approval Period |
|---|---|
| **INITIAL**<br>As monotherapy for the treatment of relapsing-remitting multiple sclerosis (MS) diagnosed according to the current clinical criteria and magnetic resonance imaging (MRI) evidence, when prescribed by a neurologist from a designated MS clinic, for patients who meet all of the following criteria:<br>1. The patient is ambulatory with or without aid (EDSS of 6.5 or less).<br>**AND**<br>2. The patient is 18 years of age or older. | 15 months |
| **RENEWAL**<br>As monotherapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have demonstrated that the therapeutic benefits outweigh any potential risks, as shown by relapse rate, EDSS, MRI scan, or overall clinical impression. | 24 months |
| **CHANGE OF THERAPY**<br>As monotherapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have experienced failure or intolerance to a previous disease modifying therapy. | 15 months |
| **DISCONTINUATION OF THERAPY**<br>Discontinuation of therapy should be discussed with patients with stable or inactive disease who are 60 years of age or older. | |
| **ADDITIONAL CRITERIA FOR INTERFERON BETA-1B (BETASERON® and EXTAVIA®)**<br>Interferon beta-1b is also eligible for PharmaCare coverage for the treatment of secondary progressive MS (initial, renewal and change of therapy). | 1 year |

## Terms of the Agreement

- The Pharmaceutical, Laboratory & Blood Services Division reserves the right to modify the Limited Coverage criteria; grant practitioner exemptions from completing Special Authority (SA) requests for prescriptions meeting the above Limited Coverage criteria; require renewals of exemptions; and, as necessary, conduct quality assurance checks of such processes. For quality assurance purposes, the neurologist with an exemption agrees to receive feedback on their prescribing of biosimilar rituximab, dimethyl fumarate, glatiramer acetate, interferon beta-1a, interferon beta-1b, and teriflunomide.
- Patients who meet the Limited Coverage criteria and whose prescription is written by a neurologist with a valid exemption will receive automatic SA coverage for subsequent claims up to the specified maximum.
- Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement and any other applicable PharmaCare pricing policy.
- Each CPA must be signed by the practitioner who is requesting coverage and not a delegate.
- PharmaCare coverage is not retroactive. SA approval or a current exemption must be in place before a patient fills an initial or refill prescription.
- For any patient who does not meet the Limited Coverage criteria, a practitioner with an exemption is required to do one of the following:
    a) Write on the prescription "Submit as zero cost to PharmaCare" to indicate to the pharmacist that the prescription should not be covered by PharmaCare; or
    b) Apply for exceptional PharmaCare coverage by submitting a SA request with full documentation (via fax to 1-800-609-4884).
- An exemption may be discontinued if the neurologist prescribes biosimilar rituximab, dimethyl fumarate, glatiramer acetate, interferon beta-1a, and interferon beta-1b, or teriflunomide in a manner inconsistent with the terms of this Agreement.
- The practitioner's contact information below will be used only to provide feedback to the practitioner on their prescribing of this drug and/or communicate changes to the Limited Coverage criteria and/or terms of this Agreement. Contact information will not be shared.

**All fields are mandatory**

| | |
|---|---|
| Name of neurologist (print) | |
| Neurologist signature | College of Physicians & Surgeons ID number |
| Address (work) | Fax number (to which confirmation of exemption should be sent) |
| Date submitted | Email |

**FAX COMPLETED AGREEMENT TO HEALTH INSURANCE BC at 1-250-405-3599**

A copy of this agreement will be kept on file at the Ministry of Health.

**Pharmaceutical, Laboratory & Blood Services Division Use Only**

| | |
|---|---|
| **Effective date**: _____<br><br>**Approval period**: Indefinite<br><br>**Approved on behalf of Pharmaceutical, Laboratory & Blood**<br><br>**Services Division**:_____<br><br>**Confirmation sent (date)**: _____ | **DBR Operational Information**:<br>ID reference number for CPSBC = 91 Category<br>and subcategory code =<br>• biosimilar rituximab 9901-0348;<br>• dimethyl fumarate 9901-0239;<br>• glatiramer acetate 9901- 0313;<br>• interferon beta-1a (Avonex®) 9901-0118;<br>• interferon beta-1a (Rebif®) 9901-0079;<br>• interferon beta-1b (Betaseron®, Extavia®) 9901-0110<br>• teriflunomide 9901-0246<br>Assumed SA = No |